Anti-tumor necrosis factor (anti-TNF) therapy effects on postoperative complications in Crohn's disease patients are unclear.
Dr Ali Syed and colleagues performed a retrospective cohort to clarify this relationship.
The team followed Crohn's disease patients at a referral center between 2004 and 2011 who underwent abdominal surgery were identified.
Postoperative complications were compared in patients exposed and unexposed to Anti-tumor necrosis factor 8 weeks preoperatively.
The team of doctors reported that demographics, surgical history, comorbidities, corticosteroid and immunomodulator use, Montreal classification, operative details, and preoperative nutritional status were assessed.
The research team measured the independent effect of preoperative anti-tumor necrosis factor on postoperative complications.
The research team noted that overall, 325 abdominal surgeries were performed, and 150 received anti-tumor necrosis factor 8 weeks before surgery.
|The anti-TNF group developed overall infectious more frequently|
|American Journal of Gastroenterology|
The anti-tumor necrosis factor group developed overall infectious, and a trend toward surgical site complications more frequently.
The team of doctors assessed that major postoperative and intra-abdominal septic complications did not differ between groups.
Multivariable analysis showed that preoperative anti-tumor necrosis factor was an independent predictor of overall infectious.
Dr Syed's team commented "In a tertiary referral center, use of anti-tumor necrosis factor therapy in Crohn's disease patients 8 weeks or less before intestinal resection or any intra-abdominal surgery was independently associated with increases in infectious and surgical complications."